# FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

> **NCT04034459** · PHASE2 · UNKNOWN · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 109 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Folinic acid
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT04034459
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-25
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2023-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034459, "FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04034459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*